Pall leukotrap affinity prion-reduction filter removes exogenous infectious prions and endogenous infectivity from red cell concentrates

Vox Sanguinis

Volumn 90, Issue 4, 2006, Pages 265-275

  Sowemimo Coker, S O ^a   Pesci, S ^a   Andrade, F ^a   Kim, A ^a   Kascsak, R B ^b   Kascsak, R J ^b   Meeker, C ^b   Carp, R ^b  

^a PALL CORPORATION   (United States)

^b NEW YORK STATE INSTITUTE FOR BASIC RESEARCH IN DEVELOPMENTAL DISABILITIES   (United States)

Author keywords

Blood; Creutzfeldt Jakob vCJD; Leucoreduction; Prion

Indexed keywords

ANTICOAGULANT AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD TRANSFUSION; BRAIN HOMOGENATE; CALIBRATION; CREUTZFELDT JAKOB DISEASE; DENSITOMETRY; DISEASE TRANSMISSION; ERYTHROCYTE CONCENTRATE; FILTER; HAMSTER; LEUKOPENIA; NONHUMAN; PALL LEUKOTRAP AFFINITY PRION REDUCTION FILTER; PERFORMANCE; PRION; PRIORITY JOURNAL; SCRAPIE; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CELL SEPARATION; CREUTZFELDT-JAKOB SYNDROME; CRICETINAE; DENSITOMETRY; ERYTHROCYTES; FILTRATION; HEMORHEOLOGY; HUMANS; LEUKOCYTES; MESOCRICETUS; PRPSC PROTEINS; SCRAPIE;

EID: 33646093707     PISSN: 00429007     EISSN: 14230410     Source Type: Journal    
DOI: 10.1111/j.1423-0410.2006.00765.x     Document Type: Article

References (35)

1. Ironside JW Head MW Variant Creutzfeldt-Jakob disease and its transmission by blood J Thromb Haemost 2003 1 479 486
2. Bernoulli C Siegfried J Baumgartner G Regli F Rabinowicz T Gajdusek DC Gibbs CJ Danger of accidental person-to-person transmission of Creutzfeldt-Jakob disease by surgery Lancet 1977 1 478 479
3. Esmonde TF Will RG Slattery JM Knight R Harries-Jones R de Silva R Mathews WB Creutzfeldt-Jakob disease and blood transfusion Lancet 1993 341 205 207
4. Wilson K Code C Ricketts M Risk of acquiring Creutzfeldt-Jakob disease from blood transfusion: systematic review of case-control studies Br Med J 2000 321 17 19
5. Vamvakas EC Risk of transmission of Creutzfeldt-Jakob disease by transfusion of blood, plasma, and plasma derivatives J Clin Apher 1999 14 135 143
6. Will RG Ironside JW Zeidler M Cousens SN Estibeiro K Alperovitch A Poser S Pocchiari M Hofman A Smith PG A new variant of Creutzfeldt-Jakob disease in the UK Lancet 1996 347 921 925
7. The National Creutzfeldt-Jakob Disease Surveillance Unit: figures for the number of CJD cases and referrals of suspected cases of CJD to the surveillance unit since 1990 (updated 6 December 2005). University of Edinburgh, UK.
8. Australian Government-Department of Health and Ageing: What is Variant Creutzfeldt-Jakob Disease (updated December 2004).
9. Houston F Foster JD Chong A Hunter N Bostock CJ Transmission of BSE by blood transfusion in sheep Lancet 2000 16 999 1000
10. Hunter N Foster J Chong A McCutcheon S Parnham D Eaton S MacKenzie C Houston F Transmission of prion diseases by blood transfusion J Gen Virol 2002 83 2897 2905
11. Brown P Rowher RG Dunstan BC MacAuley C Gajdusek DC Drohan WN The distribution of infectivity in blood components and plasma derivatives in experimental models of transmissible spongiform encephalopathy Transfusion 1998 38 810 816
12. Cervenakova L Yakovleva O McKenzie C Kolchinsky S McShaen L Drohan WN Brown P Similar levels of infectivity in the blood of mice infected with human-derived vCJD and GSS strains of transmissible spongiform encephalopathy Transfusion 2003 43 1687 1694
13. Brown P Cervenakova L McShane LM Barber P Rubenstein R Drohan WN Further studies of blood infectivity in experimental model of transmissible spongiform encephalopathy, with an explanation of why blood components do not transmit Creutzfeldt-Jakob disease in humans Transfusion 1999 39 1169 1178
14. Llewelyn CA Hewitt PE Knight RSG Amar K Couesens S Mackenzie J Will RG Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion Lancet 2004 363 417 421
15. Peden AH Head MW Ritchie DL Bell JE Ironside JW Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient Lancet 2004 364 527 529
16. United Kingdom Health Protection Agency (HPA): New case of variant CJD associated with blood transfusion (updated 9 February 2006).
17. United Kingdom Spongiform Encephalopathy Advisory Committee (SEAC): Annual Report 1997-1998. pp10. London, UK, Department of Environment, Food and Rural Affairs
18. US FDA FDA Final Guidance-Revised Preventive Measures to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease (CJD) and Variant Creutzfeldt-Jakob Disease (vCJD) by Blood, Blood Products. US Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research (CBER). January 2002
19. Gregori L McCombie N Palmer D Birch P Sowemimo-Coker SO Giulivi A Rohwer RG Effectiveness of leucoreduction for removal of infectivity of transmissible spongiform encephalopathies from blood Lancet 2004 364 529 531
20. Wadsworth JDF Joiner S Hill AF Campbell TA Desbruslais M Luthert PJ Collinge J Tissue distribution of protease resistant prion protein in variant Creutzfeldt-Jakob disease using a highly sensitive immunoblotting assay Lancet 2001 358 171 180
21. BioReliance-Invitrogen: Western Blot Assay Protocol 2005. Study number AB02UU.800037.BSV. Rockville, MD, Invitrogen
22. Sowemimo-Coker SO Kim A Tribble E Wenz B Development and validation of an accurate method for counting low levels of both normal and abnormal leukocytes in leukoreduced blood/blood components Transfusion 1998 38 Suppl 10S 11S
23. Clark MR Mohandas N Shohet SB Hosch RM Rossi ME Osmotic gradient ektacytometry: comprehensive characterization of red cell volume and surface maintenance Blood 1983 61 889 910
24. King MJ Behrens J Rogers C Flynn C Greenwood D Chambers K Rapid flow cytometric test for the diagnosis of membrane cytoskeleton associated haemolytic anaemia Br J Haematol 2000 111 924 933
25. Lee DC Stenland CJ Miller JLC Cai K Ford EK Gilligan KJ Hartwell RC Terry JC Rubenstein R Fournel M Petteway ST Jr. A direct relationship between the portioning of the pathogenic prion protein and transmissible spongiform encephalopathy infectivity during the purification of plasma proteins Transfusion 2001 41 449 455
26. Foster PR Griffin BD Bienek C McIntosh RV MacGregor IR Somerville RA Steele PJ Reichl HE Distribution of a bovine spongiform encephalopathy-derived agent over ion-exchange chromatography used in the preparation of concentrates of fibrinogen and factor VIII Vox Sang 2004 86 92 99
27. Foster PR Welch AG McLean C Griffin BD Hardy JC Bartley A MacDonald S Bailey AC Studies on the removal of abnormal prion protein by processes used in the manufacture of human plasma products Vox Sang 2000 78 86 95
28. Liao YC Lebo RV Clawson GA Smuckler EA Human prion protein cDNA: molecular cloning, chromosomal mapping, and biological implications Science 1986 233 364 367
29. Bendheim PE Bockman JM McKinley MP Kingsbury DT Prusiner SB Scrapie and Creutzfeldt-Jakob disease prion proteins share physical properties and antigenic determinants Proc Natl Acad Sci USA 1985 82 997 1001
30. Vey M Baron H Weirner T Groner A Purity of spiking agent affects partitioning of prions in plasma protein purification Biologicals 2002 September 30 187 196
31. Mohandas N Clark M Jacobs MS Shohet SB Analysis of factors regulating erythrocyte deformability J Clin Invest 1980 66 463 573
32. Chasis JA Mohandas N Erythrocyte membrane deformability and stability: two distinct membrane properties that are independently regulated by skeletal protein associations J Cell Biol 1986 63 343 350
33. Card R Mohandas N Mollison PL Relationship of post-transfusion viability to deformability of stored red cells Br J Haematol 1983 53 237 240
34. Taylor HL Whitley PH Sawyer S Averett N Johnson A Cuartas I Nelson E Lieu T Excellent in vivo 42-day red blood cell recovery and low hemolysis using a new filter designed to remove prions Transfusion 2005 45 Suppl 184 Abstract S53-040A
35. Saunders C Herbert P Rowe G Hayward M Wilkins K Milligan J Stenning M Seacombe A Prowse C In-vitro evaluation of the PALL Leukotrap Affinity Prion Reduction Filter as a secondary device following primary leucoreduction Vox Sang 2005 89 220 228